Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Quarterly results
Director comp.
Credit agrmnt [a]
Acq. announced
Appointed director
SEROLOGICALS CORP (SERO) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/05/2006 8-K Quarterly results
05/01/2006 8-K Quarterly results
Docs: "SEROLOGICALS CORPORATION REPORTS FIRST QUARTER RESULTS FIRST QUARTER REVENUE EXCEEDS EXPECTATIONS AND PRO FORMA NET INCOME UP 12.8%"
04/28/2006 8-K Credit agreement amendment
Docs: "Second Amendment to Credit Agreement and Waiver, among Serologicals, the Lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent"
04/25/2006 8-K Quarterly results, Acquisition/merger/asset purchase announced
Docs: "Agreement and Plan of Merger, by and among Millipore Corporation, Charleston Acquisition Corp. and Serologicals Corporation",
"Millipore Corporation to Acquire Serologicals Corporation"
03/27/2006 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Stock Purchase Agreement, by and among Upstate Group, L.L.C., The Ronald L. Gingerich Revocable Living Trust and Ronald L. Gingerich",
"Purchase and Sale Agreement, by and between Upstate Group, L.L.C. and Paragon Properties, L.C",
"SEROLOGICALS CORPORATION AGREES TO ACQUIRE LINCO Solidifies Serologicals as a Leader in Multiplexing Marketplace",
"Conference Call Transcript—Serologicals Corporation Acquisition Review, held on March 24, 2006 at 9:00 a.m. EST"
03/08/2006 8-K Director compensation was amended/approved
03/01/2006 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
02/27/2006 8-K Quarterly results
Docs: "SEROLOGICALS COPORATION PRESS RELEASE DATED FEBRUARY 22, 2006"
02/02/2006 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
01/10/2006 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Transcript of 2006 Guidance conference call on January 6, 2006",
"SEROLOGICALS CORPORATION ANNOUNCES PLANT RATIONALIZATION ACTIONS",
"Presentation accompanying 2006 Guidance conference call"
01/06/2006 8-K Cost Associated with Exit or Disposal Activities, Material Impairments
12/15/2005 8-K Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
10/28/2005 8-K Quarterly results
Docs: "SEROLOGICALS CORPORATION REPORTS THIRD QUARTER RESULTS REVENUES INCREASE 45% FOR THE QUARTER AND 48% FOR FIRST NINE MONTHS"
08/11/2005 8-K Quarterly results
Docs: "SEROLOGICALS CORPORATION REPORTS SECOND QUARTER RESULTS REVENUES INCREASE 46% FOR THE QUARTER AND 50% FOR FIRST SIX MONTHS"
06/10/2005 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Serologicals Corporation Amended and Restated 2005 Incentive Plan",
"SEROLOGICALS CORPORATION AUTHORIZES SHARE REPURCHASE PLAN"
05/20/2005 8-K Termination of a Material Definitive Agreement
05/17/2005 8-K Director compensation was amended/approved
Docs: "Serologicals Corporation 2005 Incentive Plan",
"Serologicals Corporation Description of Compensation Arrangements for Non-Employee Directors"
05/05/2005 8-K Quarterly results
Docs: "REVENUES INCREASE 55% AS COMPANY CONFIRMS FULL-YEAR GUIDANCE",
"Serologicals Issues Correction For Computational Error"
05/02/2005 8-K Other Events
03/15/2005 8-K Director compensation was amended/approved
Docs: "Celliance™ Announces Lawrence, KS Plant Commences Customer Audit and Product Testing Phase ATLANTA, GA—March 14, 2005"
02/25/2005 8-K Quarterly results
Docs: "SEROLOGICALS CORPORATION REPORTS FOURTH QUARTER AND FULL YEAR 2004 RESULTS RECORD SALES AND PRO FORMA EARNINGS FOR FOURTH QUARTER AND FULL YEAR",
"CHEMICON INTERNATIONAL, INC. EXPANDS STEM CELL FRANCHISE THROUGH ACQUISITION OF SPECIALTY MEDIA"
12/23/2004 8-K Asset disposition
Docs: "Exchange Agreement, between Life Therapeutics Limited and Serologicals Finance Company",
"Promissory Note, made by Life Therapeutics Limited, Life Gels, Inc., Life Therapeutics Plasma Holdings, Inc., LifeSera, Inc., LifeSera Nevada, Inc., LifeSera Business Trust, LifeSera Investments, LLC, LifeSera Management Partnership, LP, and Allegheny Biologicals, Inc. to Serologicals Finance Company",
"Mutual Release Agreement, by and among Life Therapeutics Limited, Life Gels, Inc., Life Therapeutics Plasma Holdings, Inc., LifeSera, Inc., LifeSera Nevada, Inc., LifeSera Business Trust, LifeSera Investments, LLC, LifeSera Management Partnership, LP, and Allegheny Biologicals, Inc., on the one hand, and Serologicals Corporation and Serologicals Finance Company, on the other hand",
"Opinion of King & Spalding LLP",
"SEROLOGICALS ANNOUNCES CLOSING OF PUBLIC OFFERING"
12/17/2004 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Underwriting Agreement, by and among J.P. Morgan Securities Inc., as representative of the several underwriters listed in Schedule I thereto, Serologicals Corporation and the selling stockholders listed in Schedule II thereto",
"Opinion of King & Spalding LLP",
"NEWS"
12/07/2004 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "SEROLOGICALS ANNOUNCES PLANS FOR FOLLOW-ON EQUITY OFFERING"
12/06/2004 8-K/A Financial Statements and Exhibits
Docs: "Consent of PricewaterhouseCoopers LLP",
"Audited consolidated balance sheets of Upstate Group, Inc. and Subsidiaries as of December 31, 2003 and 2002 and the related consolidated statements of operations, changes in stockholders' deficit and cash flows for each of the three years in the period ended December 31, 2003",
"Unaudited consolidated balance sheet of Upstate Group, Inc. and Subsidiaries as of September 30, 2004 and December 31, 2003 and the unaudited consolidated statements of operations and cash flows for the nine months in the periods ended September 30, 2004 and 2003",
"Unaudited pro forma combined balance sheet of Serologicals Corporation as of September 26, 2004 and unaudited pro forma combined statements of income for the fiscal year ended December 28, 2003 and the nine months ended September 26, 2004 and related notes to unaudited pro forma combined financial statements"
10/22/2004 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Conference Call Transcript—Serologicals Corporation, Q3 2004 Serologicals Corporation Earnings Conference Call, held on October 21, 2004 / 9:00AM EST"
10/21/2004 8-K Quarterly results
Docs: "SEROLOGICALS CORPORATION REPORTS THIRD QUARTER AND NINE MONTH RESULTS NET INCOME FROM CONTINUING OPERATIONS INCREASES 312% IN THIRD QUARTER AND 179% YEAR-TO-DATE"
10/20/2004 8-K Appointed a new director
Docs: "Amendment to Agreement and Plan of Merger, by and among Serologicals Corporation and Upstate Group, Inc",
"$125,000,000 Credit Agreement, among Serologicals Corporation, as Borrower, the several lenders from time to time parties thereto, LaSalle Bank National Association, as Documentation Agent, Bank of America, N.A., as Syndication Agent and JPMorgan Chase Bank, as Administrative Agent",
"Employment Agreement, between Serologicals Corporation and Ian W. Ratcliffe",
"Change in Control Executive Severance Agreement, between Serologicals Corporation and Ian W. Ratcliffe",
"Non-Competition Agreement, between Serologicals Corporation and Ian W. Ratcliffe",
"NAMES AARON J. SHATKIN, PH.D TO BOARD OF DIRECTORS"
09/10/2004 8-K Acquisition/merger/asset purchase announced
Docs: "Agreement and Plan of Merger, by and among Serologicals Corporation, Upstate Acquisition Company, LLC, Upstate Group, Inc. and the Stockholder Representative",
"SEROLOGICALS CORPORATION TO ACQUIRE UPSTATE GROUP MANAGEMENT TO HOST CONFERENCE CALL ON SEPTEMBER 8",
"Conference Call Transcript—Serologicals Corporation to Acquire Upstate Group, held on September 8, 2004 / 9:00AM EST"
08/06/2004 8-K Financial statements and exhibits, Regulation FD Disclosure
Docs: "Plan and Agreement of Merger by and among Serologicals Corporation, Carmel Acquisition Corporation, Altagen Biosciences, Inc. and William R. Srigley",
"Earnout and Indemnity Agreement by and among Serologicals Corporation, AltaGen BioSciences, Inc. and Mr. William R. Srigley",
"SEROLOGICALS CORPORATION ANNOUNCES COMPLETION OF ACQUISITION OF ALTAGEN BIOSCIENCES AND SIERRA BIOSOURCE™ SUBSIDIARY ATLANTA, GA—July 27, 2004"
07/21/2004 8-K Quarterly results
Docs: "ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.",
"Corporation, Atlanta Bud Ingalls"
07/01/2004 8-K Regulation FD Disclosure
Docs: "SEROLOGICALS IMPLEMENTS RULE 10b5-1stOCK TRADING PROGRAM"
06/30/2004 8-K Regulation FD Disclosure
Docs: "SEROLOGICALS CORPORATION ACQUIRES ALTAGEN BIOSCIENCES AND SIERRA BIOSOURCE™ SUBSIDIARY Expands R&D Capabilities and Strengthens Focus on Cell Culture Business Acquisition Expected to be Accretive in FY 2004"
04/21/2004 8-K Quarterly results
Docs: "Changed Since Last Report)",
"Serologicals Corporation Reports First Quarter Results; Revenues"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy